Health Care • Biotechnology: Pharmaceutical Preparations
$26.93 ▲ +0.60
(+2.28%)
MKT CAP: $1.15B • VOL: 371.4K
52W L $17 52W H $30
AMPH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $719.9M | $732.0M | $644.4M |
| YoY Revenue Growth % | -1.7% | +13.6% | — |
| Gross Profit | $356.1M | $373.9M | — |
| Gross Margin % | 49.5% | 51.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $140.4M | $205.4M | $197.0M |
| Operating Margin % | 19.5% | 28.1% | 30.6% |
| Net Income (GAAP) | $98.1M | $159.5M | $137.5M |
| EBITDA (Normalized) | $168.3M | $238.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $156.1M | $213.4M | $183.5M |
| Capital Expenditures (CapEx) | $34.9M | $41.0M | — |
| Free Cash Flow (FCF) | $121.2M | $172.3M | $183.5M |
| FCF Margin % | 16.8% | 23.5% | 28.5% |
| Return on Invested Capital (ROIC %) | 9.0% | 13.6% | — |
| Cash & Short-Term Equivalents | $170.2M | $151.6M | — |
| Total Debt (Short + Long Term) | $619.7M | $613.5M | — |
| Total Stockholders' Equity | $788.8M | $732.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AMPH.